S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Innocan Pharma’s VALITIC™ Brand Targets Expansion at Shoptalk Fall 2026

Nashville’s Music City Center hosts over 3,500 industry leaders this week for Shoptalk Fall 2026, an event centered on the future of consumer retail. Among those navigating the evolving landscape is B.I. Sky Global, the wellness subsidiary of Innocan Pharma, which is utilizing the conference to scale its VALITIC™ skincare line.

Innocan Pharma’s VALITIC™ Brand Targets Expansion at Shoptalk Fall 2026
Photo: Bio & News

The three-day gathering, running from September 29 through October 1, brings together executives from over 1,300 retailers and consumer brands. Under the theme "Retail Unplugged," the event prioritizes peer-to-peer strategy sessions aimed at defining operational plans for 2027. For B.I. Sky Global, the focus remains on direct engagement with retail partners to broaden distribution channels for its flagship wellness products.

Roni Kamhi, Co-Founder and CEO of B.I. Sky Global, is attending the summit to leverage the company’s experience in the U.S. consumer wellness market. According to Kamhi, the conference provides a vital venue for building relationships that support the continued growth of the VALITIC™ brand. Iris Bincovich, CEO of Innocan Pharma, noted that the brand's presence in Nashville underscores its increasing relevance within the competitive U.S. retail ecosystem, particularly as the company seeks to expand its footprint across diverse product categories.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!